Cubist Systematic Strategies’s Monte Rosa Therapeutics GLUE Stock Holding History

Cubist Systematic Strategies’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-92,818	Closed	-$644K	–	3084
2024 Q4	$644K	Buy	+92,818	New	+$697K	﹤0.01%	2050
2024 Q1	–	Sell	-10,602	Closed	-$59.9K	–	3921
2023 Q4	$59.9K	Buy	+10,602	New	+$41.6K	﹤0.01%	3252
2023 Q1	–	Sell	-24,619	Closed	-$187K	–	4089
2022 Q4	$187K	Sell	24,619 -7,787	-24%	-$64.9K	﹤0.01%	3609
2022 Q3	$265K	Buy	+32,406	New	+$298K	﹤0.01%	3595
2021 Q4	–	Sell	-10,731	Closed	-$239K	–	3521
2021 Q3	$239K	Buy	+10,731	New	+$308K	﹤0.01%	2485

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Cubist Systematic Strategies's GLUE Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Monte Rosa Therapeutics (GLUE) in Q1 2025, closing a stake of 92,818 shares — an estimated $644K sold.

Cubist Systematic Strategies first reported a position in GLUE in Q3 2021 and held it in 5 quarters. The position peaked at $644K in Q4 2024. 105 funds tracked by Wall St. Rank hold GLUE as of Q1 2025.

Cubist Systematic Strategies reported no remaining Monte Rosa Therapeutics position as of Q1 2025 after selling out during the quarter.
Cubist Systematic Strategies sold 92,818 Monte Rosa Therapeutics shares in Q1 2025, an estimated $644K.
Cubist Systematic Strategies first reported a position in Monte Rosa Therapeutics in Q3 2021 and held it in 5 quarters.
Cubist Systematic Strategies's Monte Rosa Therapeutics position peaked at $644K in Q4 2024.
105 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.